vs
艾伯维（ABBV）与Encompass Health Corp（EHC）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Encompass Health Corp的10.8倍（$16.6B vs $1.5B）。艾伯维净利率更高（10.9% vs 9.5%，领先1.5%）。艾伯维同比增速更快（10.0% vs 9.9%）。艾伯维自由现金流更多（$4.9B vs $116.7M）。过去两年艾伯维的营收复合增速更高（16.2% vs 8.3%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Encompass Health Corp前身为Amcare及HealthSouth，总部位于美国阿拉巴马州伯明翰，是美国规模最大的住院康复服务提供商，在39个州及波多黎各拥有173家住院康复医院，为中风、神经系统疾病、心肺病症、脑损伤等患者提供专业康复诊疗服务。
ABBV vs EHC — 直观对比
营收规模更大
ABBV
是对方的10.8倍
$1.5B
营收增速更快
ABBV
高出0.1%
9.9%
净利率更高
ABBV
高出1.5%
9.5%
自由现金流更多
ABBV
多$4.8B
$116.7M
两年增速更快
ABBV
近两年复合增速
8.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $1.5B |
| 净利润 | $1.8B | $146.1M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | 16.7% |
| 净利率 | 10.9% | 9.5% |
| 营收同比 | 10.0% | 9.9% |
| 净利润同比 | 8354.5% | 20.8% |
| 每股收益（稀释后） | $1.02 | $1.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVEHC
| Q4 25 | $16.6B | $1.5B | ||
| Q3 25 | $15.8B | $1.5B | ||
| Q2 25 | $15.4B | $1.5B | ||
| Q1 25 | $13.3B | $1.5B | ||
| Q4 24 | $15.1B | $1.4B | ||
| Q3 24 | $14.5B | $1.4B | ||
| Q2 24 | $14.5B | $1.3B | ||
| Q1 24 | $12.3B | $1.3B |
净利润ABBVEHC
| Q4 25 | $1.8B | $146.1M | ||
| Q3 25 | $186.0M | $126.5M | ||
| Q2 25 | $938.0M | $142.1M | ||
| Q1 25 | $1.3B | $151.5M | ||
| Q4 24 | $-22.0M | $120.9M | ||
| Q3 24 | $1.6B | $108.2M | ||
| Q2 24 | $1.4B | $114.1M | ||
| Q1 24 | $1.4B | $112.5M |
毛利率ABBVEHC
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVEHC
| Q4 25 | 27.3% | 16.7% | ||
| Q3 25 | 12.1% | 14.9% | ||
| Q2 25 | 31.7% | 16.2% | ||
| Q1 25 | 28.0% | 16.4% | ||
| Q4 24 | -9.9% | 14.3% | ||
| Q3 24 | 26.5% | 13.6% | ||
| Q2 24 | 27.6% | 14.3% | ||
| Q1 24 | 22.7% | 13.6% |
净利率ABBVEHC
| Q4 25 | 10.9% | 9.5% | ||
| Q3 25 | 1.2% | 8.6% | ||
| Q2 25 | 6.1% | 9.7% | ||
| Q1 25 | 9.6% | 10.4% | ||
| Q4 24 | -0.1% | 8.6% | ||
| Q3 24 | 10.8% | 8.0% | ||
| Q2 24 | 9.5% | 8.8% | ||
| Q1 24 | 11.1% | 8.5% |
每股收益（稀释后）ABBVEHC
| Q4 25 | $1.02 | $1.43 | ||
| Q3 25 | $0.10 | $1.24 | ||
| Q2 25 | $0.52 | $1.39 | ||
| Q1 25 | $0.72 | $1.48 | ||
| Q4 24 | $-0.03 | $1.18 | ||
| Q3 24 | $0.88 | $1.06 | ||
| Q2 24 | $0.77 | $1.12 | ||
| Q1 24 | $0.77 | $1.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $72.2M |
| 总债务越低越好 | $58.9B | $2.4B |
| 股东权益账面价值 | $-3.3B | $2.4B |
| 总资产 | $134.0B | $7.1B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资ABBVEHC
| Q4 25 | $5.3B | $72.2M | ||
| Q3 25 | $5.7B | $48.7M | ||
| Q2 25 | $6.5B | $99.1M | ||
| Q1 25 | $5.2B | $95.8M | ||
| Q4 24 | $5.6B | $85.4M | ||
| Q3 24 | $7.3B | $147.8M | ||
| Q2 24 | $13.2B | $154.4M | ||
| Q1 24 | $18.1B | $134.4M |
总债务ABBVEHC
| Q4 25 | $58.9B | $2.4B | ||
| Q3 25 | $63.0B | $2.4B | ||
| Q2 25 | $63.0B | $2.3B | ||
| Q1 25 | $64.5B | $2.3B | ||
| Q4 24 | $60.3B | $2.4B | ||
| Q3 24 | $58.5B | $2.3B | ||
| Q2 24 | $58.0B | $2.7B | ||
| Q1 24 | $63.8B | $2.7B |
股东权益ABBVEHC
| Q4 25 | $-3.3B | $2.4B | ||
| Q3 25 | $-2.6B | $2.4B | ||
| Q2 25 | $-183.0M | $2.3B | ||
| Q1 25 | $1.4B | $2.2B | ||
| Q4 24 | $3.3B | $2.1B | ||
| Q3 24 | $6.0B | $2.0B | ||
| Q2 24 | $6.8B | $1.8B | ||
| Q1 24 | $8.0B | $1.7B |
总资产ABBVEHC
| Q4 25 | $134.0B | $7.1B | ||
| Q3 25 | $133.9B | $6.9B | ||
| Q2 25 | $137.2B | $6.8B | ||
| Q1 25 | $136.2B | $6.6B | ||
| Q4 24 | $135.2B | $6.5B | ||
| Q3 24 | $143.4B | $6.5B | ||
| Q2 24 | $141.9B | $6.4B | ||
| Q1 24 | $148.9B | $6.2B |
负债/权益比ABBVEHC
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | 45.44× | 1.08× | ||
| Q4 24 | 18.15× | 1.14× | ||
| Q3 24 | 9.70× | 1.20× | ||
| Q2 24 | 8.56× | 1.46× | ||
| Q1 24 | 7.97× | 1.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $346.0M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $116.7M |
| 自由现金流率自由现金流/营收 | 29.4% | 7.6% |
| 资本支出强度资本支出/营收 | 2.0% | 14.8% |
| 现金转化率经营现金流/净利润 | 2.87× | 2.37× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $439.2M |
8季度趋势，按日历期对齐
经营现金流ABBVEHC
| Q4 25 | $5.2B | $346.0M | ||
| Q3 25 | $7.0B | $270.8M | ||
| Q2 25 | $5.2B | $270.2M | ||
| Q1 25 | $1.6B | $288.6M | ||
| Q4 24 | $7.0B | $278.8M | ||
| Q3 24 | $5.4B | $267.8M | ||
| Q2 24 | $2.3B | $217.4M | ||
| Q1 24 | $4.0B | $238.8M |
自由现金流ABBVEHC
| Q4 25 | $4.9B | $116.7M | ||
| Q3 25 | $6.6B | $83.7M | ||
| Q2 25 | $4.9B | $113.3M | ||
| Q1 25 | $1.4B | $125.5M | ||
| Q4 24 | $6.8B | $80.1M | ||
| Q3 24 | $5.2B | $120.3M | ||
| Q2 24 | $2.0B | $60.5M | ||
| Q1 24 | $3.8B | $99.4M |
自由现金流率ABBVEHC
| Q4 25 | 29.4% | 7.6% | ||
| Q3 25 | 42.1% | 5.7% | ||
| Q2 25 | 31.7% | 7.8% | ||
| Q1 25 | 10.5% | 8.6% | ||
| Q4 24 | 44.7% | 5.7% | ||
| Q3 24 | 35.9% | 8.9% | ||
| Q2 24 | 14.0% | 4.6% | ||
| Q1 24 | 31.3% | 7.6% |
资本支出强度ABBVEHC
| Q4 25 | 2.0% | 14.8% | ||
| Q3 25 | 2.4% | 12.7% | ||
| Q2 25 | 1.7% | 10.8% | ||
| Q1 25 | 1.8% | 11.2% | ||
| Q4 24 | 1.9% | 14.1% | ||
| Q3 24 | 1.7% | 10.9% | ||
| Q2 24 | 1.7% | 12.1% | ||
| Q1 24 | 1.6% | 10.6% |
现金转化率ABBVEHC
| Q4 25 | 2.87× | 2.37× | ||
| Q3 25 | 37.76× | 2.14× | ||
| Q2 25 | 5.49× | 1.90× | ||
| Q1 25 | 1.27× | 1.90× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | 3.49× | 2.48× | ||
| Q2 24 | 1.66× | 1.91× | ||
| Q1 24 | 2.95× | 2.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
